-
Study aim
-
Determining and comparing the effect of studied herbal medicine in decreasing mortality and hospitalization of patients with COVID-19.
-
Design
-
A randomized open-label (without-blinding) clinical trial, with the parallel groups on 150 pateints
-
Settings and conduct
-
This randomized open-label clinical trial study was performed on 150 eligible patients with QUID-19, referring to Amin and Al-Zahra hospitals in Isfahan and were randomly divided into 2 groups. The first group receives herbal capsules in addition to the standard treatment and the second group receives only the standard treatment. Then, at the end of the intervention the mortality, and hemodynamic parameters of patients will be evaluated and compared between the two groups.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria include the age range of 40-80 years, weighing more than 50 kg, definitive infection with Covid 19, being in the acute and critical phase of the disease, and consent to participate in the study.
Exclusion criteria included pregnancy, breastfeeding, the existence of active ulcers in the gastrointestinal tract, taking digoxin, admission to the ward before the start of the study, and a history of allergies to medicinal plants.
-
Intervention groups
-
Intervention group: Patients in this group receive standard treatment. In addition, they will be prescribed 2 one-gram oral capsules every 8 hours. The capsules contain 500 mg of honey and 500 mg of oily extract of the studied plant compounds in equal proportions.
Control group: Patients in this group will receive only standard treatments.
-
Main outcome variables
-
Need for mechanical ventilation; Duration of hospitalization; Need to be admitted to the intensive care unit; death; Number of breaths; heart rate; Interleukin 6; Percentage of oxygen saturation; Lymphocyte level, platelet level